Francesca Barone
Chief Tech/Sci/R&D Officer at CANDEL THERAPEUTICS, INC.
Net worth: 294 918 $ as of 2024-03-30
Profile
Francesca Barone is currently the Chief Scientific Officer at Candel Therapeutics, Inc. She previously worked as the Director-laboratories at the Institute of Translational Medicine.
From 2010 to 2019, she was an Associate Professor at the University of Birmingham.
In 2019, she became the Head-Experimental Medicine at Senda Biosciences, Inc. Dr. Barone holds a doctorate degree from Sapienza University of Rome and King's College London.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-11-27 | 186,657 ( 0.65% ) | 294 918 $ | 2024-03-30 |
Francesca Barone active positions
| Companies | Position | Start |
|---|---|---|
| CANDEL THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2020-10-31 |
Former positions of Francesca Barone
| Companies | Position | End |
|---|---|---|
Senda Biosciences, Inc.
 Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 2020-10-31 |
| University of Birmingham | Corporate Officer/Principal | 2019-04-30 |
| Institute of Translational Medicine | Corporate Officer/Principal | - |
Training of Francesca Barone
| Sapienza University of Rome | Doctorate Degree |
| King's College London | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CANDEL THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Senda Biosciences, Inc.
Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
| Institute of Translational Medicine |
- Stock Market
- Insiders
- Francesca Barone
